Back to Screener

Healthcare

Spyre Therapeutics, Inc.(SYRE)

Live Price

Offline

$88.34

+0.97% today

1Y Change

+401.70%

Window

Jun 23, 2025 โ†’ Jun 5, 2026

Market Cap
$4.19B
Revenue Growth
0.0%
EPS Growth
+37.7%
Dividend Yield
0.0%

Coverage: 240 bars ยท Jun 23, 2025 โ†’ Jun 5, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Spyre Therapeutics, Inc. (SYRE) is a Healthcare stock with a market cap of $4.19B and listed on NASDAQ. The stock last traded around $88.34 and up 401.7% across the available one-year price window (Jun 23, 2025 โ†’ Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.7%, free cash flow -7.5% with operating margin -231.6% and ROIC -29.1%. Valuation already assumes a fairly strong business story at price/sales 46.3. Stock Foundry combines SYRE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-231.6% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 14, 2026, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +37.7%, while operating margin sits near -231.6%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged +4.7% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 14, 2026
โ€”-1.0%-1.8%โ€”
2026
Feb 19, 2026
-6.1%+14.3%+14.1%+11.9%
2025
Nov 4, 2025
+77.9%-0.6%+1.6%+40.1%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SYRE

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SYRE Max Drawdown

-16.79%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SYRE and SPY.

Calendar-year return history is still loading or unavailable.
Spyre Therapeutics, Inc. logo

Company Overview

Spyre Therapeutics, Inc.

NASDAQ Capital Market

Waltham, MA, US
Visit spyre.comCall IR617 651 5940

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4รŸ7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4รŸ7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4รŸ7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Leadership
Cameron Turtle
IPO Date
Apr 7, 2016
Employees
73
Street Address
221 Crescent Street
Mailing
Waltham, MA, 02453
Region
Waltham, MA, US
Reporting Currency
USD
Investor Line
617 651 5940
Last Updated
May 5, 2026
CIK: 0001636282ISIN: US00773J2024CUSIP: 00773J202
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
46.3
Price/Book
33.6

Growth

Revenue
0.0%
EPS
+37.7%
Free Cash Flow
-7.5%

Profitability

Gross Margin
0.0%
Operating Margin
-231.6%
Net Margin
-171.5%
ROE
-29.4%
ROIC
-29.1%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
13.25

Earnings Reports

๐Ÿ“… Last reportedMay 14, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 14, 26
โ€”
Est -0.67
โ€”
โ€”
Est 70870.9B
โ€”
โ€”
Feb 19, 26
โœ—
-0.70
Est -0.66
-6.1%
90494.0B
Est 142857.0B
-36.6%
โ€”
Nov 4, 25
โœ“
-0.15
Est -0.68
+77.9%
โ€”
Est โ€”
โ€”
โ€”
Aug 5, 25
โœ“
-0.49
Est -0.73
+32.9%
โ€”
Est โ€”
โ€”
โ€”
May 8, 25
โœ“
-0.74
Est -0.76
+2.6%
โ€”
Est โ€”
โ€”
โ€”
Feb 27, 25
โœ“
-0.81
Est -0.89
+9.0%
โ€”
Est 4000.0B
โ€”
โ€”
Nov 7, 24
โœ—
-1.36
Est -0.80
-70.0%
โ€”
Est 2625.0B
โ€”
โ€”
Aug 7, 24
โœ“
-0.86
Est -0.90
+4.4%
โ€”
Est 4000.0B
โ€”
โ€”
May 9, 24
โœ—
-1.20
Est -0.90
-33.3%
โ€”
Est โ€”
โ€”
โ€”
Feb 29, 24
โœ—
-2.28
Est -0.48
-375.0%
1042.0B
Est 220.0B
+373.6%
โ€”
Nov 9, 23
โœ—
-9.34
Est -0.84
-1011.9%
โ€”
Est 198.0B
โ€”
โ€”
Aug 11, 23
โœ“
-1.66
Est -4.50
+63.1%
688.0B
Est 198.0B
+247.5%
โ€”
Mar 31, 23
โœ—
-4.89
Est -4.50
-8.6%
198.0B
Est 184.0B
+7.6%
โ€”
Dec 30, 22
โœ—
-7.20
Est -5.71
-26.1%
168.0B
Est 133.3B
+26.0%
โ€”
Sep 29, 22
โœ“
-4.84
Est -6.25
+22.6%
174.0B
Est 208.3B
-16.5%
โ€”
Jun 29, 22
โœ“
-6.79
Est -7.95
+14.6%
625.0B
Est 709.5B
-11.9%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks